Vaccines now account for only 3% of pharmaceutical industry profits,
so they have stopped investing in them. Millions may die as a result
An Ebola outbreak in London, Dengue Fever in Moscow, Malaria sweeping
through Italy, a typhoid epidemic in Portugal or a cholera outbreak in Madrid
are not figments of the Hollywood imagination, but a distinct possibility.
(Pravda)
-- At the OECD conference in the Gulbenkian Foundation in Lisbon on Tuesday,
it was claimed that if the pharmaceutical industry in the developed countries
does not pay enough attention to tropical diseases in the Less Developed
Countries (LDCs), these diseases may very well invade the northern hemisphere.
Apart from the threat posed by the frequency of air travel, the phenomenon
of global warming creates the climate for dangerous insects to live and
breed, at least for a short time, in warmer springs and autumns in countries
where tropical diseases were thought to be something a careless traveller
caught in Africa. Not any more.
In Africa, malaria kills three thousand children per day, every day.
AIDS is rife, diseases like Ebola appear with growing frequency. Without
a global programme for vaccine production, warns the Portuguese Institute
of Molecular and Cellular Biology, these problems could spread beyond
the frontiers of Africa. And they are.
For Bernard Kouchner, ex-Minister of Health in France, “This problem
is political and not one pertaining to microbiology”. He added that
what is missing is pressure by public opinion, because so long as people
do not care whether diseases, like doctors, can become “diseases
without frontiers”, then governments will not allocate resources
to combat the problem.
M. Kouchner pointed out that while life expectancy is 43 years of age
in LDCs and 83 in EU countries, it is natural that people from the developing
world will come to the developed countries for treatment “not as
invaders, but as people like us”.
However, it is not only in LDCs where infectious diseases are contracted,
as Philippe Kourilsky, of the Pasteur Institute, pointed out: “Nobody
is safe from infectious diseases”. While there are situations in
which less than one per cent of medicines are allocated to the treatment
of tropical diseases and while there are zero resources for outbreaks
of these diseases in LDCs, the prospect is bleak: these diseases will
increase and spread.
Malaria and viral and bacterial meningitis are examples: even when laboratories
produce substances which could be transformed into vaccines, governments
are too often reluctant to translate this action into a reaction, forever
fearful of the bottom line produced by the personnel in their treasuries.
While people are dying thousands of kilometres away, the political pressure
is weak at home, until the number of sick people with relatives in the
“host country” start to arrive in droves for treatment, or
until enough people from the “host country” itself start to
appear for treatment. When the alarm bells start ringing, it may be too
late.
Vaccines count for three per cent of the profit-making products for pharmaceutical
products. For this reason, Pharma companies have ceased to invest in them,
as a rule. The action is, as always, governed by the bottom line. The
reaction may very well be much more meaningful than this.
|